psychollatine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

psychollatine: from Psychotria umbellata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	46878353
CHEMBL ID	606760
MeSH ID	M0483543

Synonyms (2)

Synonym
CHEMBL606760
psychollatine

Research Excerpts

Overview

Psychollatine is a monoterpene indole alkaloid produced and accumulated by Psychotria umbellata Vell.

Excerpt	Reference	Relevance
"Psychollatine is a monoterpene indole alkaloid produced and accumulated by Psychotria umbellata Vell. "	( Antioxidant and antimutagenic properties of the monoterpene indole alkaloid psychollatine and the crude foliar extract of Psychotria umbellata Vell. do Nascimento, NC; e Silva, AC; Fett-Neto, AG; Fragoso, V; Moura, DJ; Richter, MF; Saffi, J, 2008)	2.02

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (54)

Assay ID	Title	Year	Journal	Article
AID380146	Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 50 mg/kg, ip administered 30 mins prior to NMDA challenge	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377507	Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 100 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378495	Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 100 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377501	Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 7.5 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378494	Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 7.5 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377481	Effect on locomotory activity in CF1 mouse assessed as reduction in spontaneous activity at 100 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380148	Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 100 mg/kg, ip administered 30 mins prior to NMDA challenge	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377491	Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 3 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378498	Anxiolytic activity against CF1 mouse assessed as reduction in number in head dips at 200 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380150	Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 7.5 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377492	Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 7.5 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380155	Decrease in spontaneous locomotor activity in mouse at 100 mg/kg	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377493	Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 10 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378499	Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 7.5 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380159	Protective effect against amphetamine-induced lethality in mouse at 100 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID380151	Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 10 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID378506	Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 15 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378500	Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 7.5 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377477	Potentiation of pentobarbital-induced sleeping time in CF1 mouse at 100 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380147	Anticonvulsant activity against NMDA-induced seizures in mouse assessed as seizure latency at 75 mg/kg, ip administered 30 mins prior to NMDA challenge	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID378505	Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 15 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380157	Protective effect against amphetamine-induced lethality in mouse at 10 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377494	Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 30 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378509	Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 3 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377478	Potentiation of pentobarbital-induced sleeping time in CF1 mouse at 2 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380154	Decrease in spontaneous locomotor activity in mouse at 10 mg/kg	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID380161	Inhibition of apomorphine-induced climbing behavior in mouse at 10 mg/kg, ip administered 30 mins prior to apomorphine challenge	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377466	Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377499	Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 0.85 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377495	Anxiolytic activity against CF1 mouse assessed as suppression of oxotremorine-treated tremors at 100 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377484	Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions for 60 mins	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378497	Anxiolytic activity against CF1 mouse assessed as reduction in number in crossings at 200 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377467	Anxiolytic activity against CF1 mouse assessed as increase in number of crossings at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377479	Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 3 to 30 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377486	Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 7.5 mg/kg during final 4 mins of the 6 mins session by forced swimming test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380153	Decrease in spontaneous locomotor activity in mouse at 7.5 mg/kg	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377480	Effect on locomotory activity in CF1 mouse assessed as change in spontaneous activity at 0.75 and 0.85 mg/kg	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377487	Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 10 mg/kg during final 4 mins of the 6 mins session by forced swimming test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378501	Anxiolytic activity against CF1 mouse assessed as increase in number of head dips at 7.5 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377476	Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 7.5 mg/kg in presence of ritanserin for 5 mins	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380152	Antipsychotic activity against MK-801-induced hyperlocomotion in mouse at 100 mg/kg administered 30 mins prior to MK-801 challenge measured after 30 mins	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377471	Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 7.5 mg/kg for 5 mins	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380158	Protective effect against amphetamine-induced lethality in mouse at 30 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
AID377498	Effect on short term memory of CF1 mouse assessed as reduction in latency during aquisition at 100 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377506	Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 7.5 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378508	Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 30 mg/kg during final 4 mins of the 6 mins session by forced swimming test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377468	Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 7.5 mg/kg after 30 mins in presence of ritanserin by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377485	Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 3 mg/kg during final 4 mins of the 6 mins session by forced swimming test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377472	Anxiolytic activity against CF1 mouse assessed as increase in latency to enter in the dark compartment 7.5 mg/kg for 5 mins	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377475	Anxiolytic activity against CF1 mouse assessed as increase in time spent in light compartment at 7.5 mg/kg in presence of ritanserin for 5 mins	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID378507	Anxiolytic activity against CF1 mouse assessed as increase in number of rearings at 15 mg/kg after 30 mins by hole-board assay	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377502	Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 10 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID377503	Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 30 mg/kg by by passive avoidance test	2005	Journal of natural products, Mar, Volume: 68, Issue:3	Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID380156	Protective effect against amphetamine-induced lethality in mouse at 3 mg/kg, ip administered 30 mins prior to amphetamine challenge measured after 24 hrs	2006	Journal of natural products, Mar, Volume: 69, Issue:3	Role of glutamate and dopamine receptors in the psychopharmacological profile of the indole alkaloid psychollatine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.50 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.30 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.03	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.03	1	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.43	2	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.02	1	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.02	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.02	1	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.03	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	2.04	1	organic cation	geroprotector; herbicide
dizocilpine [no description available]	2.02	1	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
glycosides [no description available]	3.14	5
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.03	1	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
scopolamine hydrobromide [no description available]	2.02	1
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.04	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger

chemdatabank.com